Back to company

Innosurge Biologics A/S: Financial statements 2025

CVR: 38768964

Innosurge Biologics A/S (CVR 38768964) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 4,455,235 and a net result of DKK 1,662,593 compared with DKK 251,617 the year before. That is an increase of 82.2% compared with the year before. Equity amounted to DKK 2,897,096. The solvency ratio was 51.1%. The company had 2 employees in the financial year.

Gross Profit
4,455,235 kr.
Profit/Loss
1,662,593 kr.
Equity
2,897,096 kr.
Total Assets
5,664,786 kr.
Employees
2

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2025-4.5 mio.1.7 mio.2.9 mio.2
2024-2.4 mio.252 t.2 mio.2
2023-2.1 mio.407 t.1.7 mio.2
2022-2.2 mio.490 t.1.3 mio.3
2021-993 t.-613 t.836 t.3

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like Innosurge Biologics A/S

Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.

Try the lead list generator

Events in 2025

Innosurge Biologics A/S: The 2024 annual report is outJun 29, 2025

Innosurge Biologics A/S has published its annual report for 2024. Gross profit came to DKK 2,444,975, and the net result was DKK 251,617.

About Innosurge Biologics A/S

Innosurge Biologics A/S is a Danish company of the type Aktieselskab based in Randers NV, founded in 2017. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The management consists of Peter Møller Lassen. The company is owned by CMA HOLDING RANDERS ApS. The company has 1 employee. In 2025, the company reported a gross profit of DKK 4,455,235 and a net result of DKK 1,662,593 compared with DKK 251,617 the year before. Equity amounted to DKK 2,897,096.

Other financial years